Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Inks Second Off-Label Settlement With DoJ, Paying $72.5 Million Over TOBI Marketing

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis still faces government investigations over its marketing of five other drugs; FDA issues a warning letter over its promotion of Gleevec on two company-sponsored websites.

You may also be interested in...



Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review

HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.

The Era Of Billion Dollar Pharma Settlements

Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.

Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year

CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel